Many mutant p53 proteins (mutp53s) exert oncogenic gain-of-function (GOF) properties, but the mechanisms mediating these functions remain poorly defined. We show here that GOF mutp53s inhibit AMP-activated protein kinase (AMPK) signaling in head and neck cancer cells. Conversely, downregulation of GOF mutp53s enhances AMPK activation under energy stress, decreasing the activity of the anabolic factors acetyl-CoA carboxylase and ribosomal protein S6 and inhibiting aerobic glycolytic potential and invasive cell growth. Under conditions of energy stress, GOF mutp53s, but not wild-type p53, preferentially bind to the AMPKa subunit and inhibit AMPK activation. Given the importance of AMPK as an energy sensor and tumor suppressor that inhibits anabolic metabolism, our findings reveal that direct inhibition of AMPK activation is an important mechanism through which mutp53s can gain oncogenic function.
INTRODUCTION
Mutation of the TP53 tumor suppressor gene is one of the most frequent genetic alterations in cancer, including head and neck squamous cell carcinoma (HNSCC) (Agrawal et al., 2011; Stransky et al., 2011) . Although mutation of the TP53 gene can result in loss of wild-type p53 (wtp53) function or exert a dominant-negative effect over the remaining wild-type allele, some mutated forms of p53 (mutp53s) can lead to a gain of oncogenic properties that promote tumor growth and progression. However, the mechanisms involved in mutp53 gain of function (GOF) remain relatively poorly understood (Oren and Rotter, 2010) .
Metabolic alterations, particularly the metabolic reprogramming to aerobic glycolysis (i.e., the Warburg effect) and the reprograming of mitochondrial metabolism, represent a hallmark of cancer that contributes to malignant transformation as well as the growth and maintenance of tumors (Hanahan and Weinberg, 2011; Vander Heiden et al., 2009; Ward and Thompson, 2012) . In vivo dynamic mechanisms such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian homolog of target of rapamycin (mTOR) and adenosine monophosphate (AMP)-activated protein kinase (AMPK) sense the cellular energy status and regulate the balance between anabolism (an adenosine triphosphate [ATP]-consuming process that leads to macromolecular synthesis) and catabolism (a process that degrades marcomolecules to release energy through increased ATP production) (DeBerardinis and Thompson, 2012) . AMPK is a highly conserved heterotrimeric serine/threonine protein kinase complex composed of a catalytic a subunit and regulatory b and g subunits. As a major cellular energy sensor and a master regulator of metabolic homeostasis, AMPK is sensitive to the cellular AMP:ATP and adenosine diphosphate:ATP ratios and is activated by metabolic stresses that inhibit ATP production or stimulate ATP consumption . Once activated, AMPK stimulates catabolism while inhibiting anabolism. AMPK achieves these effects by targeting many downstream metabolic enzymes (e.g., acetyl-CoA carboxylase [ACC] and mTOR) and by phosphorylating transcription factors (e.g., sterol regulatory element-binding protein 1 [SREBP1]) or cofactors that regulate gene expression Mihaylova and Shaw, 2011) .
Studies have shown that wtp53 can regulate many metabolic pathways, such as carbohydrate and lipid metabolism, ROS regulation, and autophagy (Berkers et al., 2013; Goldstein and Rotter, 2012) . Importantly, stimulation of AMPK leads to the phosphorylation and activation of wtp53 (Jones et al., 2005; Okoshi et al., 2008) . However, it remains unclear whether wtp53 is the direct target of AMPK (Fogarty and Hardie, 2010; Hardie, 2011) . Recently, AMPK was shown to promote the stability of wtp53 indirectly through phosphorylation and inactivation of MDMX (He et al., 2014) and the p53 deacetylase, SIRT1 (Lee et al., 2012) . The activation of wtp53 by AMPK signaling is believed to establish a metabolic checkpoint to suppress the growth of cells under conditions of metabolic stress (Jones et al., 2005) . Therefore, AMPK is considered a tumor suppressor (Faubert et al., 2013; Luo et al., 2010) . Moreover, once activated, wtp53 can, in turn, increase AMPK activity through transcriptional activation of the gene encoding the b subunit of AMPK (Feng et al., 2007) and sestrin (Budanov and Karin, 2008) , providing a positive feedback effect to AMPK function. This positive feedback between AMPK and wtp53 is believed to play an important role in tumor suppression.
The vast majority of mutant p53s arise from missense mutations that can cause significant alterations in tertiary structure ) which, in turn, can cause changes in p53 function through altered protein-protein interactomes and/or altered regulation of gene expression, thereby contributing to mutp53 GOF properties (Freed-Pastor and Prives, 2012; Muller and Vousden, 2013; Solomon et al., 2012) . Recently, mutp53s were also shown to regulate metabolic pathways, such as steroid metabolism, via regulation of the transcription factor SREBP , a downstream target of AMPK that directly phosphorylates and inhibits SREBP activity ). In the current study, we show that AMPK signaling is inhibited by GOF mutp53s. Moreover, we show that GOF mutp53s, but not wtp53, preferentially bind to the AMPKa subunit and directly inhibit AMPK activation, which increases anabolic growth and contributes to the GOF properties of mutp53s.
RESULTS mutp53s Gain Oncogenic Function to Promote Invasive Growth of HNSCC Cells Both In Vitro and In Vivo
To study the functional impact of TP53 mutations, we first selected several human tumor-derived HNSCC cell lines with various TP53 status ( Figures 1A and 1B ) with which to test the function of mutp53s. When treated with the DNA-damaging agent 5-fluorouracil (5-FU), all the cell lines with mutp53s appeared to have lost wtp53 transcriptional function, as shown by the lack of induction of expression of the wtp53 targets, MDM2 and p21 ( Figure 1B) . One HNSCC cell line tested, UMSCC1, was found to lack detectable endogenous p53 protein due to the instability of splice site mutants ( Figures 1A and 1B , and see Figure S1 online). This cell line was then stably transfected with various mutp53s ( Figure 1C ) to evaluate whether they could confer GOF activity. Overexpression of mutp53s P151S, R175H, G245C, and R282W in UMSCC1 cells promoted invasive cell growth, as characterized by the formation of larger tumor spheroids with longer migration and invasion distances in an inverted three-dimensional (3D) Matrigel culture when compared with retroviral vector pBabe ( Figure 1D ), whereas expression of the C-terminal truncation mutp53, E336X, did not significantly promote UMSCC1 cell growth in the same assay ( Figure 1D ).
In further support of mutp53 GOF, we used lentivirusmediated p53 short hairpin RNA (shp53RNA) interference to knock down the expression of endogenous mutp53s ( Figure 1E ). Suppression of endogenous mutp53 R175H and P151S expression in Detroit 562 and Tu138 cells, respectively, resulted in smaller tumor spheroids with less migration and invasion compared with the control ( Figure 1F ). To further support the idea that mutp53 P151S is a GOF mutant, we previously demonstrated that overexpression of mutp53 P151S in UMSCC1 cells led to increased tumor growth and decreased animal survival in a mouse orthotopic xenograft oral tumor model. Conversely, downregulation of mutp53 P151S in Tu138 cells suppressed tumor growth and increased animal survival in the same model (Sano et al., 2011) .
Collectively, our in vitro and in vivo results clearly demonstrated that certain mutp53s, such as P151S, R175H, G245C, and R282W, gain oncogenic function to promote invasive cell growth, whereas the C-terminal truncation mutp53, E336X, exhibits limited or no significant GOF activities in UMSCC1 cells.
Overexpression of GOF mutp53s Inhibits AMPK Activation
The formation of larger tumor spheroids in 3D Matrigel by overexpression of GOF mutp53s in UMSCC1 cells could have been due to an increase in cell proliferation, cell growth (cell size), or both, which is strongly linked to mTOR signaling (Zoncu et al., 2011) . Consistent with this, downregulation of mutp53 P151S in Tu138 cells resulted in a slightly smaller cell size when cells were cultured under low-glucose culture condition ( Figure S2A ). Because wtp53 is involved in inhibiting mTOR signaling by modulating both positive (PI3K/AKT) and negative (liver kinase B1 [LKB1]/AMPK) upstream regulatory pathways of mTOR signaling (Feng and Levine, 2010) , we then examined AKT and AMPK signaling in our stable cell lines expressing mutp53s. Interestingly, while no difference in AKT phosphorylation was observed in UMSCC1 stable cell lines ( Figures 2D-2F ), we noted that the induction of AMPKa Thr 172 phosphorylation, which is required for AMPK kinase activation (Hawley et al., 1996) , in response to glucose deprivation, 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AICAR), and metabolic stress (serum-free, glucose-free, and hypoxia) was inhibited in UMSCC1 cells expressing mutp53 R175H when compared with the control cell line lacking mutp53 expression ( Figures  2A-2C ). However, under the same conditions, AMPK activation was only minimally affected in cells expressing the C-terminal truncated, non-GOF mutp53 E336X (Figures 2A-2C ). We then examined whether other GOF mutp53s have similar inhibitory effects on AMPK signaling in UMSCC1 cells. Under subconfluent culture condition two mutp53s, P151S and R175H, but not G245C and R282W, efficiently inhibited phosphorylation of AMPKa as well as ACC, a downstream target of AMPK (Winder et al., 1997) , in response to glucose deprivation ( Figures 2D) . However, when cells were cultured under highdensity cell culture condition, all GOF mutp53s, including G245C and R282W, which did not inhibit AMPK activation in subconfluent culture, inhibited AMPK activation in response to glucose deprivation when compared with the control ( Figures  2E and S2B) . Importantly, this inhibition appeared to be specific to GOF mutp53s, since overexpression of neither non-GOF mutp53 E336X nor wtp53 inhibited AMPK activation under the same condition (Figures 2A-2C and 2F ). To understand why all GOF mutp53s inhibited AMPK activation (AMPKa Thr 172 phosphorylation), we further used quantitative reverse transcription PCR (RT-qPCR) and western blotting to examine the possible role of transcription control involved in mutp53-mediated AMPK inhibition. Our results, however, showed no inhibition of mutp53s to expression of the subunits of AMPK and its upstream LKB1 kinase complexes (i.e., AMPKa/b/g and LKB1/Mo25a/ b/Strada/b) that are directly involved in AMPK activation in response to energy stress in UMSCC1 cells .
To further test the role of GOF mutp53s in AMPK signaling, we used mouse embryonic fibroblasts (MEFs) with or without mutp53 R172H/H (equivalent to human mutp53 R175H/H ), which was shown to have GOF activity in a genetically engineered mouse model (Lang et al., 2004; Olive et al., 2004) . Compared with control p53 À/À MEF cells, mutp53 R172H/H MEFs exhibited lower levels of induction of AMPK and ACC phosphorylation in response to glucose starvation under confluent culture condition (Figures 2G and 2H) . Taken together, our results showed that unlike wtp53, which activates AMPK signaling (Budanov and Karin, 2008; Feng et al., 2007) , GOF mutp53s can actually inhibit AMPK activation and AMPK signaling.
Downregulation of GOF mutp53s Enhances AMPK Activation Induced by Energy Stress
As further evidence that GOF mutp53s inhibit AMPK activation, knockdown of endogenous mutp53 P151S in Tu138 cells (Figures 3A and 3B) , and mutp53 R175H in pharyngeal cancer Detroit 562 cells ( Figure 3C ) and breast cancer SKBR3 cells (Figure 3D) resulted in increased induction of AMPK and ACC phosphorylation in response to glucose deprivation or metabolic stress. In contrast, we did not observe any impact of downregulation of wtp53 on AMPK activation in response to glucose deprivation in HN30 cells ( Figure S3 ). Additionally, consistent with the role of AMPK as a negative regulator of the mTOR/S6 ribosomal protein pathway (Shackelford and Shaw, 2009 ), downregulation of mutp53 P151S in Tu138 cells resulted in decreased phosphorylation of the S6 ribosomal protein in response to glucose deprivation ( Figure 3E ), presumably through enhanced AMPK signaling. Moreover, immunohistochemical (IHC) evaluation of orthotopically grown oral cancer xenografts derived from Tu138-control shRNA (Ctr) and Tu138-shp53 cells (Sano et al., 2011) confirmed that Tu138-shp53 tumors exhibit increased levels of phosphorylated AMPK (pAMPK) and ACC (pACC) compared with Tu138-Ctr tumors ( Figure 3F ).
Finally, introducing an shRNA-resistant version of mutp53 R175H or P151S into Detroit 562 shp53 or Tu138 shp53 cells by retroviral infection partially restored mutp53 expression in these cells, which not only led to decreased levels of energy stress-induced pAMPK (Figures 3G and 3H) but also partly rescued the invasive growth and prevented the phenotypic regression of Detroit 562 shp53 cells in 3D Matrigel culture ( Figure 3I ). These results, taken together, further supported our hypothesis that GOF mutp53s negatively regulate AMPK activation and signaling and contribute to the invasive growth phenotype of HNSCC cells both in vitro and in vivo.
Energy Stress Induces the Interaction of GOF mutp53s and AMPK In Vivo
In vivo, AMPK is shuttled between the nucleus and cytoplasm (Kodiha et al., 2007) . However, cytoplasm is where AMPK is activated by its upstream kinase in response to energy stress (Tsou et al., 2011) . To investigate the mechanisms involved in mutp53-mediated AMPK inhibition, we first examined the subcellular localization, especially the cytoplasmic localization, of mutp53s in UMSCC1 cells. Immunofluorescent staining revealed that GOF mutp53 P151S was localized in both the nucleus and cytoplasm of UMSCC1 cells ( Figure 4A ). In contrast, mutp53 E336X, likely because of its lack of a C-terminal p53 nuclear export signal (residues 340-351) (Stommel et al., 1999) , localized exclusively in the nucleus of UMSCC1 cells ( Figure 4B ). Since this mutp53 E336X could not inhibit AMPK activation in vivo (Figures 2A-2C) , the subcellular localization of mutp53s (i.e., the cytoplasmic localization) might be critical for mutp53-mediated AMPK inhibition. Consistent with this notion, GOF mutp53 G245C, which could only efficiently inhibit AMPK activation in high-density cell culture (compare Figures 2E and 2D) , was predominantly localized to the nucleus in low-density cell culture ( Figure 4C ). However, its increased cytoplasmic localization was seen when cell density was increased ( Figure 4C ), suggesting that the stress from high-density cell culture facilitates the cytoplasmic localization of this mutp53.
Next, we investigated whether mutp53s could interact with AMPK in vivo. To this end, we first transfected 293FT human embryonic kidney cells with green fluorescent protein (GFP)-tagged AMPKa2 and Myc-tagged mutp53 R175H. Our results showed that mutp53 R175H was strongly associated with the GFPAMPKa2 complex but not with control GFP ( Figure 4D ). Similarly, when Myc-tagged GOF mutp53s P151S, R175H, G245C, and R282W were transfected, they were all able to complex with hemagglutinnin (HA)-tagged AMPKa2 expressed in 293FT cells (Figure 4E , lanes 5-8; Figure S4 ). In contrast, neither transfected wtp53 nor the nucleus-localized mutp53 E336X was able to complex with HA-tagged AMPKa2 in the same assay ( Figure 4E , compare lanes 4 and 9 to lanes 5-8), suggesting that compared to wtp53 and E336X, GOF mutp53s (i.e., P151S, R175H, G245C, and R282W) gain the capability to interact with AMPKa2 in 293FT cells.
The interaction of GOF mutp53s P151S, R175H, G245C, and R282W with endogenous AMPKa was also observed in UMSCC1 cell lines stably expressing these mutp53s ( Figure 4F ) and in different HNSCC cell lines expressing various endogenous mutp53s ( Figures 4G-4K ), whereas no interaction between AMPKa and wtp53 or nucleus-localized mutp53 E336X was detected under the same conditions . Our results further showed that although endogenous GOF mutp53s P151S and R175H weakly interacted with the endogenous AMPKa in Tu138 and Detroit 562 cells under normal culture conditions, the enhanced interaction between mutp53s and AMPKa could actually be induced by glucose deprivation ( Figures 4J and 4K ), suggesting that energy stress induces AMPKa-mutp53s interaction in vivo. Finally, our results confirmed that in the immunoprecipitated mutp53-AMPKa complex from Detroit 562 cells, the b and g subunits of AMPK were also detected ( Figures 4H and 4L ), suggesting that GOF mutp53s interact not only with endogenous a subunit of AMPK but also with endogenous AMPK(a/b/g) holoenzyme in vivo.
Taken together, these results clearly showed not only that the interaction between GOF mutp53s and AMPK (a/b/g) occurs in vivo but also that it is induced by energy stress.
mutp53s, but Not wtp53, Preferentially Bind to AMPKa and Inhibit AMPK Activation To investigate whether mutp53s can directly interact with AMPKa, we performed glutathione S-transferase (GST) pull-down assays using either AMPKa2-6xHis expressed in bacteria ( Figure 5B ) or in vitro transcribed and translated AMPKa ( Figures 5C and 5D ) and purified bacterially expressed wild-type and mutant GSTp53 proteins (Figures 5A-5D ). Similar to our in vivo results, the GST pull-down assay demonstrated that mutp53s were indeed able to directly interact with both AMPKa1 and AMPKa2 in vitro ( Figures 5B-5D ) and that both the DNA-binding domain (DBD) and the C terminus of p53 were required for p53-AMPKa interaction ( Figures 5A and 5B) . Interestingly, it appeared that all the GSTp53 fusion proteins tested, including GST fusion proteins of wtp53 and mutp53 E336X, that did not interact with AMPKa in vivo (Figures 4E, 4F , and 4I-4K) interacted with AMPKa directly in vitro in a GST pull-down assay ( Figure 5A-5D ). Since p53 is a very sensitive molecule and one amino acid change often converts wtp53 into a mutp53 with a different conformation, the fusion protein tag may significantly affect the p53 molecule. To minimize the impact of the N-terminal GST tag (27KD) on p53 conformation and physical properties, we further purified and used C-terminal 6xHis (1KD)-tagged p53 proteins in an in vitro coimmunoprecipitation (coIP) assay. The results indicated that wtp53 had a much weaker binding affinity to AMPKa2 than did GOF mutp53s ( Figure 5E ). This observation was confirmed with an enzyme-linked immunosorbent assay (ELISA)-based protein-binding assay ( Figure S5A ).
To test whether the direct binding of AMPKa can inhibit its activation (a-Thr 172 phosphorylation) by upstream kinases, we carried out in vitro kinase assays using the active AMPK upstream kinase, LKB1 or TGF-b-activated kinase-1 (TAK1), and AMPKa1 or AMPKa2 substrates in the presence or absence of purified GST-tagged cleaved wtp53 or different mutp53s. Under these experimental conditions, AMPKa-Thr 172 was efficiently phosphorylated by LKB1 or TAK1, and AMPKa phosphorylation was strongly inhibited by mutp53s, whereas no inhibition was observed when similar amounts of wtp53 or the N-terminal deletion D161 mutant were used (Figures 5F, 5G, and S5B). Given that both GST-wtp53 and GST-D161 bound to AMPKa ( Figures 5A-5D ) but the GST-tagged cleaved wtp53 or D161 did not inhibit AMPKa Thr 172 phosphorylation ( Figures 5F and 5G ), the binding itself may be insufficient to block the activation of AMPK, and the inhibition of a-Thr 172 phosphorylation by upstream kinases may require an N-terminally intact p53 with the ''mutant molecular conformation.'' In support of this notion, our in vitro pull-down assay using different purified proteins showed that although wtp53 and the mutants D161, R175H, and D161-R175H all bound to AMPKa2, only the GOF mutant R175H efficiently inhibited AMPKa2-LKB1 interaction (Figure 5H) . Therefore, whereas DBD is required for p53-AMPKa binding ( Figures 5A and 5B ), the N terminus of mutp53s is responsible for blocking AMPKa-LKB1 interaction ( Figure 5H ).
Finally, since active AMPK is a heterotrimeric serine/threonine protein kinase complex that contains not only an a subunit (catalytic subunit) but also regulatory b and g subunits , after demonstrating that mutp53s could bind to the a subunit and inhibit its Thr 172 phosphorylation by upstream kinases ( Figures 5A-5H ), we investigated whether mutp53s can directly affect AMPK activation as well as its subsequent kinase activity. To test this idea, we first cotransfected 293FT with GFPAMPKb1 and HA-AMPKa2, and then used Chromotek-GFPTrap agarose beads to pull down AMPK (a/b/g), which was further dephosphorylated by phosphatase PP2C. Subsequently, this dephosphorylated AMPK (inactive kinase) was used in a linked LKB-mediated AMPKa-Thr 172 phosphorylation/AMPK activity assay in the presence or absence of different wtp53 and mutp53s ( Figure 5I, left) . The mutp53s R175H, G245C, P151S, and E336X were also able to inhibit a-Thr 172 phosphorylation and suppress activation of AMPK by LKB1, subsequently suppressing its kinase activity ( Figure 5I , right). In contrast, wtp53 that bound to AMPKa weakly ( Figure 5E ) and the DDBD mutp53 that did not bind to AMPKa ( Figure 5B ) exhibited either marginal or no impact on a-Thr 172 phosphorylation and AMPK activation by LKB1 ( Figure 5I, right) .
Taken together, our results demonstrated that mutp53 directly binds to the AMPKa subunit via the DBD, while its N terminus blocks the interaction between AMPKa and upstream kinases, leading to inhibition of AMPK activation and AMPK kinase activity.
Inhibition of AMPK Rescues Both Decreased Invasive Cell Growth and Impaired Aerobic Glycolytic Potential Associated with Loss of GOF mutp53s
Consistent with the tumor-suppressing role of AMPK, knockdown of AMPKa1 in p53-deficient UMSCC1 and PCI-13 cells promoted cell growth in 3D Matrigel (Figures S6A-S6D ). To further test the role of inhibition of AMPK activation in the GOF mutp53-associated phenotype, we knocked down AMPKa in mutp53 downregulated cells. While downregulation of mutp53 P151S in Tu138 cells resulted in decreased S6 phosphorylation in response to glucose starvation, further knockdown of AMPKa2 in those cells by two independent shRNAs rescued the decreased phosphorylation of ribosomal protein S6 due to the loss of mutp53 P151S ( Figure 6A ).
Because ribosomal protein S6 is a critical downstream mediator of mTOR regulation of protein synthesis and cell growth (Zoncu et al., 2011) , we expected that GOF mutp53s would enhance cell growth (i.e., cell size) through S6 activation. Flow cytometry analysis demonstrated that downregulation of mutp53 P151S in Tu138 cells resulted in a slight but consistent MOLCEL 5043
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Gain-of-Function Mutant p53 Inhibits AMPK decrease in the cell size of both G1 and G2/M cells cultured in low-glucose medium (0.5 mM glucose) ( Figure 6B ). More important, the decrease in cell size induced by the loss of mutp53 was rescued by knockdown of AMPKa2 expression in Tu138 shp53RNA cells ( Figure 6B) . Similarly, downregulation of AMPKa2 in Tu138 shp53RNA and Detroit 562 shp53RNA cells rescued the impaired invasive cell growth associated with loss of mutp53s in an in vitro 3D Matrigel culture assay, which resulted in much larger and more disorganized tumor spheroids with longer migration/invasion distances ( Figures 6C-6E and S6E-S6H). Furthermore, introducing an shRNA-resistant version of AMPKa2 into mutp53-and AMPKa1&2-double knockdown Tu138 and Detroit 562 cells by retroviral infection (Figures 6D  and S6G ) reversed the phenotype, leading to smaller cell size ( Figure S6I ) and decreased invasive cell growth with less cell migration and invasion in an inverted 3D Matrigel culture ( Figures  6E and S6H ). Together, these results strongly suggested that AMPK is an important downstream target of GOF mutp53s and a critical mediator of the observed cell growth and invasive phenotype associated with mutp53 GOF. Phosphorylation of ACC and SREBP-1c by AMPK leads to inhibition of ACC and SREBP-1c activity, resulting in increased fatty acid oxidation and decreased lipogenesis (Hardie and Pan, 2002; Li et al., 2011) . Given the inhibitory role of GOF mutp53s on AMPK, we expected that GOF mutp53s would also regulate lipid metabolism. Consistent with this idea, p53 (R172H/H) MEFs treated with a combination of insulin, rosiglitazone, dexamethasone, and isobutylmethylxanthine, which stimulates lipogenesis (Esfandiari et al., 2007) , exhibited much higher lipid levels than p53 À/À MEFs did as evaluated by oil red O staining ( Figure 6F ). Finally, we examined the role of mutp53s in aerobic glycolysis and mitochondrial oxidative phosphorylation (OXPHOS), as measured by the extracellular acidification rate (ECAR) and the oxygen consumption rate (OCR) (Marshall et al., 2011) . Although downregulation of mutp53 had no obvious impact on OXPHOS response ( Figures S7A and S7B) , it significantly impaired aerobic glycolytic capacity in response to glucose stimulation in both Detroit 562 and Tu138 cells ( Figures 6G, 6H, S7C, and S7D) . Furthermore, an shRNA-resistant mutp53 P151S rescued the impaired aerobic glycolytic capacity in Tu138 shp53RNA cells ( Figure S7D ). More important, the impaired aerobic glycolytic capacity due to the loss of mutp53 was partially rescued by further knockdown of AMPKa ( Figures 6G, 6H , and S7E). However, this rescue was reversed by expression of an shRNA-resistant AMPKa2 in mutp53-and AMPKa1&2-double knockdown Tu138 cells, leading to decreased aerobic glycolytic capacity in response to glucose stimulation ( Figure 6H ).
Taken together, these results suggested that GOF mutp53s are involved in promoting the invasive growth and metabolism of cancer cells, such as lipid synthesis or accumulation and aerobic glycolysis, at least partly through the inhibition of AMPK.
GOF mutp53s Promote Tumor Growth and Inhibit AMPK Activation in Orthotopic Xenografts and GOF mutp53
Genetically Engineered Mouse Models of HNSCC In support of the tumor-suppressing role of AMPK, downregulation of AMPKa in p53-deficient PCI-13 cells ( Figure S6A ) resulted in increased tumor growth in an orthotopic mouse oral cancer model ( Figure S7F ). To further gain insight into mutp53 GOF activity in the same animal tumor model, we injected UMSCC1 stable cell lines expressing different WT and different mutp53s into the tongues of nude mice. GOF mutp53s R175H, G245C, and R282W, but not mutp53 E336X, significantly accelerated tumor onset and promoted tumor growth when compared with wtp53 and pBabe control ( Figures 7A and S7G) . Moreover, while pBabe and wtp53 tumors appeared to grow in defined areas and exhibited a more differentiated morphology, GOF mutp53 tumors displayed a more aggressive phenotype and often infiltrated and invaded into adjacent tissues ( Figure 7B ). Consistently, IHC staining indicated that AMPK activation (AMPKa-Thr 172 phosphorylation) was inhibited in tumors derived from UMSCC1 stable cell lines expressing GOF mutp53s R175H, G245C, and R282W when compared with the controls ( Figure 7C ). Finally, using a genetically defined mouse model in which oral papillomas arise from the activation of endogenous oncogenic K-ras, in the presence or absence of additional GOF mutp53 R172H or loss-of-function (p53
) mutations (Acin et al., 2011) , we evaluated whether GOF mutp53s modulate AMPK activation. pAMPK was highly expressed in the basal and suprabasal layers of the papilloma of p53 À/À tumors (black arrows), whereas in GOF mutp53 R172H/-papilloma, mutp53 happened to be highly expressed in the same layers, but with decreased levels of pAMPK (red arrows) ( Figure 7D ), suggesting that expression of mutp53 R172H in tumors inhibits AMPK activation and thereby promotes tumor progression.
DISCUSSION
In the current study, we have shown that GOF mutp53s negatively regulate the metabolic effects of AMPK signaling, leading to increased lipid production, aerobic glycolysis, and invasive wtp53/mutp53 proteins. Shown is a representative result that was conducted simultaneously for both AMPKa1 and AMPKa2. Relative quantitative data (mean ± SD) from two independent experiments were calculated from gel densitometry using NIH imaging software and are shown at top. The activity of R175H was used as the referent (100%).
(E) In vitro coIP/IB assay using purified WT/mutp53-6xHis and AMPKa2-6xHis proteins.
(legend continued on next page) cell growth. Moreover, our results demonstrated that GOF mutp53s, through their DBDs, preferentially bind to the AMPKa subunit, whereas their N termini block AMPKa-LKB1 interaction, leading to inhibition of AMPK activation. On the basis of these results, we propose a working model whereby mutp53s can gain functional activity ( Figure 7E ): GOF mutp53s with high AMPKa-binding affinity gain oncogenic function to promote cell growth and cancer cell metabolism through direct inhibition of AMPK activation. The majority of p53 missense mutations occur in the DBD, which usually leads to loss of the specific DNA-binding activity of p53 as a transcription factor that directly regulates gene expression. In spite of this, while missense mutations disrupt the specific p53 DNA-binding activity, they often cause significant alterations in p53 tertiary structure , which in turn can cause changes in p53 function through altered protein-protein interactomes and/or altered regulation of gene expression, contributing to mutp53 GOF properties (FreedPastor and Prives, 2012; Muller and Vousden, 2013; Solomon et al., 2012) . As an excellent example, our results demonstrated a difference between wtp53 and mutp53s in terms of their ability to bind AMPKa and inhibit AMPK activation both in vitro and in vivo ( Figures 2F, 4E , 4F, 4J, 5E-5I, 7C, and S3-S5), suggesting an important molecular mechanism for the difference between mutp53s and wtp53 in their abilities to interact with other proteins, regulate gene expression, and exert GOF properties.
Most mutp53 GOF mechanisms that have been proposed are involved in transcriptional control of gene expression, in which mutp53s function as either transcriptional coactivators or transcriptional corepressors to control the transcriptional machinery that regulates gene expression (Freed-Pastor and Prives, 2012; Muller and Vousden, 2013; Solomon et al., 2012) . Among many possible GOF mechanisms, dominant-negative effects over other p53 family members, p63 and p73, were proposed (Li and Prives, 2007) . Interestingly, TAp63 was reported to transcriptionally activate LKB1 and AMPKa2 expression in mouse fat, liver, and muscle in a TAp63-knockout mouse model (Su et al., 2012) , raising the possibility that GOF mutp53s inhibit LKB1 and AMPKa gene expression through dominant-negative effects over TAp63. However, while our evidence demonstrated that GOF mutp53s inhibit AMPK activation (Figures 2-7) , our results using both real-time reverse-transcriptase PCR ( Figure S2C ) and western blotting ( Figures 2D-2F and 3C ) revealed that expression of mutp53s had no significant impact on the expression of either LKB1 or AMPKa or on other subunits of LKB1 and AMPK kinases in HNSCC cells. Instead, all our evidence has indicated that GOF mutp53s have a direct role in AMPK activation (Figures 4 and 5) .
As another piece of evidence supporting the transcriptionindependent role of GOF mutp53s, our results showed that although the C-terminal-truncated mutp53 E336X exhibited both AMPKa-binding and -inhibitory activity in vitro ( Figures  5A-5D , 5F, 5G, and 5I), it failed to efficiently bind AMPKa ( Figures 4E, 4F , 4I, and 4K) or inhibit AMPK activation ( Figures  2A-2C ) in vivo and also failed to promote tumor cell growth ( Figures 1D and S7G) . The fact that E336X localized exclusively in the nucleus ( Figure 4B ) suggested that the cytoplasmic localization of mutp53s is also important for their GOF activities. Consistent with this notion, a previous study reported that some mutp53 proteins localize in the cytoplasm and inhibit autophagy (Morselli et al., 2008) . More important, our results showed that like AMPK, whose subcellular localization (e.g., the cytoplasmic localization) is influenced by cell density (Kodiha et al., 2007) , the subcellular localization of mutp53s was subjected to the regulation of cell culture conditions such as cell density ( Figure 4C ). This finding may be important to understanding the biological functions of mutp53s.
AMPK was recently identified to negatively regulate the Warburg effect through inhibition of the hypoxia-induced factor 1 (HIF1) pathway (Faubert et al., 2013) . Therefore, the inhibition of AMPK by GOF mutp53s, which relieves the suppression of HIF1 by AMPK, is expected to increase HIF1 protein expression and thus lead to increased glucose influx and glycolysis. Indeed, mutant p53s have been shown to promote HIF1 expression (Kamat et al., 2007) , and HIF1 has been found to be required for thymic lymphomas to develop in a p53 mutant mouse model (Bertout et al., 2009) .
In summary, our evidence strongly supports a transcriptionindependent mechanism that is important to the GOF activity of mutp53s. Moreover, since AMPK is a master cellular energy sensor and a regulator of metabolic homeostasis, our demonstration that mutp53s are actively involved in the regulation of cancer metabolism through direct inhibition of AMPK further extends our understanding of the molecular mechanisms of mutp53s in cancers. Our findings also provide an excellent example of how a gene mutation in tumor cells can transform an agonistic relationship (i.e., wtp53 activating AMPK signaling) into an antagonistic relationship (i.e., mutp53 inhibiting AMPK). In this case, p53 mutation transforms a signaling network with tumor-suppressing functions into a network with oncogenic potential to promote tumor growth and progression.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures.
Establishment of Stable Cell Lines Over-or Underexpressing Target Genes
Stable cell lines overexpressing a mutp53 or K-ras were obtained from pooled cells after puromycin (1-2 mg/ml) selection of retrovirus-infected cells. Lentiviral shRNA expression systems were used to stably knock down mutp53 or AMPKa expression.
(F and G) LKB1 (F) and TAK1 (G) in vitro kinase assays using 50 ng of purified GST-AMPKa1 as the substrate in the presence of the exact amount of bovine serum albumin (BSA) (1-4 mg) or various purified GST-wtp53/mutp53 proteins as indicated on Coomassie blue gel for each reaction (30 ml of total assay volume). Kinase assays were conducted in the presence of Xa factor to cleave the N-terminal GST tag of p53 proteins. In Vitro Inverted Matrigel Culture A total of 40,000 cells, mixed and embedded in 50 ml of BD-Matrigel (#354230; BD Biosciences), were layered on the surface of a BD BioCoat control insert (#354578; BD Biosciences) and incubated at 37 C for 30-45 min, allowing the Matrigel to solidify. An additional 200 ml of Matrigel was layered on the surface of the solidified Matrigel. When all the Matrigel was solidified, inserts were placed in a 24-well culture plate with 0.1 ml of serum-free culture medium in each lower chamber. On the upper side of the inserts, 0.3-0.5 ml of culture medium containing 20% fetal bovine serum (FBS) and 50 ng/ml epidermal growth factor (EGF) was added (see also Supplemental Experimental Procedures).
Glycolysis and OXPHOS Measurements
Glycolysis and OXPHOS were measured as ECAR and OCR, respectively, using Seahorse XF24 extracellular flux analyzers according to the manufacturer's instructions. 
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